HR¾­Àí ÃæÒé ÊÕ²Ø ÉêÇëְλ
Ê×Ò³ > Ì©ÖÝÕÐÆ¸ > HR¾­Àí

HR¾­Àí

Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾

Ë¢ÐÂÓÚ£º2015-12-04±»ä¯ÀÀ£º1038´Î

ÃæÒé

²»ÏÞ / ±¾¿Æ / ÐÔ±ð²»ÏÞ / ÃæÒé / ²»ÏÞµ½¸Ú

½­ËÕ-Ì©ÖÝ £¨Ì©ÖÝÒ½Ò©¸ßм¼Êõ²úÒµÔ°¿Ú̩·Î÷²à½¼Ò·¶«²àG79´± £© Éϰà·Ïß²éѯ

ÕÐÆ¸ÃæÒé

³Â
ְλ·¢²¼ÈË£º³ÂÏÈÉú

139****6549,052****713092 ÏÔʾºÅÂë

(ÁªÏµÊ±Çë˵Ã÷ÊÇÔÚÐÂÌ©ÖÝÈ˲ÅÍøÉÏ¿´µ½µÄ)

´òµç»°Ç°ÏÈͶ¸ö¼òÀú£¬»ñµÃÃæÊԵijɹ¦ÂÊÔö¼Ó30%

Ì©ÖÝÈ˲ÅÍøÌáʾ£ºÌ©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾ÎÞȨÊÕÈ¡ÈκηÑÓã¬Çë¹ã´óÇóÖ°Õß¼ÓÇ¿×ÔÎÒ±£»¤Òâʶ£¬°´ÀͶ¯·¨¹æ±£»¤×ÔÉíÈ¨Òæ£¬¾¯ÌèÐé¼ÙÕÐÆ¸,±ÜÃâÉϵ±ÊÜÆ­£¡ ¾Ù±¨´Ëְλ
ְλÃèÊö

¸ÚλְÔð£º1¸ºÔðÈËÁ¦×ÊÔ´Ïà¹ØÖÆ¶ÈÁ÷³ÌÓ빤×÷¼Æ»®µÄÖÆ¶¨£»

2¸ºÔð¹«Ë¾ÕÐÆ¸ÓëÅàѵ¹¤×÷£»

3¸ºÔð¹«Ë¾Ð½³êÓ븣Àû¹¤×÷£»

4¸ºÔð×éÖ¯Ìåϵ¹ÜÀíÓ뼨Ч¹ÜÀí¹¤×÷£»

5¸ºÔðÆäËû¸÷ÏîÈËʹÜÀí¹¤×÷¡£
¸ÚλҪÇó£º1ÈËÁ¦×ÊÔ´¹ÜÀí¹¤É̹ÜÀíµÈÏà¹Ø×¨Òµ£¬±¾¿Æ¼°ÒÔÉÏѧÀú£»

25ÄêÒÔÉÏÈËÁ¦×ÊÔ´¹¤×÷¾­Ñ飬3ÄêÒÔÉÏÉúÎïÒ©ÆóÈËʹÜÀí¾­Ñ飻

3ÊìϤÈËʹÜÀíµÈÏà¹Ø·¨ÂÉ£¬¼«Ç¿µÄ¼Æ»®¿ØÖÆ×éÖ¯¹µÍ¨ÄÜÁ¦£¬½ÏÇ¿µÄÎÄ×ÖÓëÓïÑÔ±í´ïÄÜÁ¦£¬Ò»¶¨µÄ¼ÆËã»ú°ì¹«¼°ÍøÂçʹÓü¼ÄÜ£»

4ÓÅÐãµÄÖ°ÒµËØÖʼ°Á¼ºÃµÄ·þÎñÒâʶ£¬¹¤×÷»ý¼«½øÈ¡£
¬¸»ÓÐÍŶӺÏ×÷¾«Éñ£»

ÉÏ°àµØÖ·£ºÌ©ÖÝÒ½Ò©¸ßм¼Êõ²úÒµÔ°

¹«Ë¾¼ò½é
Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾ÓÚ2015ÄêÈëפ̩ÖÝÊÐÖйúÒ½Ò©³Ç£¬×¢²á×ʱ¾2000ÍòÃÀÔª¡£¹«Ë¾Ö÷Òª´Óʵ¥¿¹Ò©ÎïÉú²ú£¬Í¶×Ê×ܶî2ÒÚÃÀÔª£¬Ä⽨³§·¿Ãæ»ý3ÍòÓàÆ½·½£¬½¨Éè·ûºÏGMP±ê×¼µÄ¹ú¼ÊÏȽøµÄ¿¹ÌåÒ©ÎïÖÆ±¸Ìåϵ£¬ÒÔÆÚ´òÔì¹úÄÚ¿¹ÌåÒ©ÎïÉú²ú¸ßµØ¡£Âõ²©Ì«¿ÆÒ©ÒµÓÉÉϺ£ÕŽ­ÉúÎï¼¼ÊõÓÐÏÞ¹«Ë¾£¨¿¹ÌåÒ©ÎïÓë°ÐÏòÖÎÁƹú¼ÒÖØµãʵÑéÊÒ£©¿¹ÌåÑз¢ÍŶÓÌṩһվʽƽ̨·þÎñ£¬ÖÂÁ¦ÓÚʵÏÖһϵÁÐÖØÁ¿¼¶¹ú¼Ò´´Ð¿¹ÌåÒ©ÎïµÄ²úÒµ»¯¡£ÏÖÓÐÆ·ÖÖ£ºÖÎÁƽáÖ±³¦°©µÄÖØ×鿹EGFRÈËÊóǶºÏµ¥¿Ë¡¿¹Ì壬ÖÎÁÆÒøÐ¼²¡µÄÖØ×éÈËLFA3-¿¹ÌåÈںϵ°°×µÈ¡£TaizhouMabtechPharmaceuticalCo.,Ltd.joinedtheChinaMedicalCity(CMC)in2015withregisteredcapitalofUSD20million,expandinganationalhighlandformonoclonalantibodymedicinemanufacturingbyestablishinginternationallyadvancedantibodymedicinemanufacturesystemwithadoptedcGMPstandards,withatotalinvestmentofUSD200million.Supportedbytheone-stopplatformfortherapeuticmAbmedicinedevelopmentprovidedbyZJ-BioR&DTeam(StateKeyLaboratoryofAntibodyMedicineandTargetedTherapy),TaizhouMabtechPharmaceuticsCo.,Ltdisdedicatedtoindustrializationofaseriesof¡°blockbuster¡±innovativeantibodydrugs.Existingvarieties:recombinantanti-EGFRhuman/mouse-chimericmonoclonalantibodyforthetreatmentofcolorectalcancer,recombinanthumanLFA3-antibodyfusionproteinforthetreatmentofpsoriasis,etal.
¸Ã¹«Ë¾µÄÆäTAְλ
Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾
  • ÖÆÔìÒµ
  • ÍâÉÌͶ×ÊÆóÒµ
  • ½­ËÕ-Ì©ÖÝ
  • 100-1000ÈË
0%¼òÀú·´À¡ÂÊ
0ƽ¾ù»Ø¸´Ê±³¤
0¸öÕÐÆ¸Ö°Î»
ְλÃû³Æ£ºHR¾­Àí
¹«Ë¾Ãû³Æ£º Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾
 
ÏàËÆÖ°Î»